Featured news from NHIVNA
HIV-related news from NAM
Longer time to virological failure and less drug resistance seen in people taking Atripla than in people taking separate drugs
Gus Cairns, 2014-09-09 10:20:00
An analysis of people who experienced treatment failure on their first-line HIV
therapy with a viral load of over 400 copies/ml and who had taken either the triple-combination
pill Atripla (tenofovir/emtricitabine/efavirenz), regimens containing its component drugs as separate pills, or regimens
substituting lamivudine for emtricitabine has found that, although
the rate of virological failure was no higher in people taking separate pills rather than Atripla, they developed
virological failure faster and were more likely to develop drug resistance.
This study has implications for the replacement of combination
pills like Atripla with individual
generic drugs as a cost-saving strategy as HIV drugs come off patent.